Longitudinal Tracking of Bone Marrow Plasma Cell Responses to Licensed Human Vaccines

NCT07493460

Status	RECRUITING
Phase	Phase 4
Sponsor	Washington University School of Medicine
Enrollment	25 participants

Key Eligibility Criteria

Inclusion (7)

- Healthy participants over 18 years of age.
- Able to understand and give informed consent.
- Willing to receive TIV, Tdap, HPV, and HAV vaccinations
- In stable health, as determined by medical history and targeted physical exam related to this history.
- Willing to give BMA samples

... and 2 more (see full listing online)

Exclusion (13)

- Has a history of severe allergic reaction to any component of the TIV, Tdap, HPV, or HAV vaccines, including allergic reactions to neomycin, yeast or prior severe reaction after vaccination including anaphylaxis or encephalopathy within 7 days of vaccination.
- Has a current or previous diagnosis of immunocompromising condition to include human immunodeficiency virus, immune-mediated disease requiring immunosuppressive treatment, or other immunosuppressive condition.
- Has received systemic immunosuppressants or immune-modifying drugs for \> 14 days in total within 6 months prior to Screening (for corticosteroids e 10 mg/day of prednisone equivalent) or is anticipating the need for immunosuppressive treatment at any time during participation in the study.
- Is acutely ill or febrile (temperature \>38.0 C \[100.4F\] less than 72 hours prior to or at the day 1 visit. Participants who meet this criteria may be rescheduled.
- Currently has symptomatic acute or unstable chronic disease requiring medical or surgical care, to include significant change in therapy or hospitalization, at the discretion of the investigator.

... and 8 more (see full listing online)

Locations (1 total)

Washington University School of Medicine Infectious Disease Clinical Research Unit, St Louis, Missouri, United States